Influence of age on the clinical efficacy of tigecycline in severely ill patients

Objectives: The aim of this study was to define the relationship between age and response to tigecycline among patients treated for complicated skin and soft-tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs). Methods: Pooled data derived from five European observational studies on the use of tigecycline (July 2006–October 2011), either as monotherapy or in combination with other antibiotics, for the treatment of cSSTI or cIAI were used in the analysis. Results: The total population (N = 1782 patients) was divided into three age categories: <65 years (804 patients); 65–80 years (836 patients) and >80 years (139 patients) (data unknown/missing for 3 patients). The overall mean Acute Physiology and Chronic Health Evaluation (APACHE) II score for patients with cSSTI and cIAI was 15.0 ± 7.9 and 16.9 ± 7.6, respectively, and the overall mean Sequential Organ Failure Assessment (SOFA) score was 5.8 ± 3.9 and 7.0 ± 4.2, respectively. Overall, patients with cSSTI and cIAI in the three age groups showed a good response to tigecycline treatment (76.2–80.0% and 69.2–81.1%, respectively) with patients aged ≤80 years showing higher response rates. Patients with cIAI appeared to be at greater risk for all types of adverse events compared with those with cSSTI, particularly in the older age groups. Conclusion: In these real-life studies, tigecycline, either alone or in combination, achieved favourable clinical response rates in all age categories of patients with cSSTIs and cIAIs with a high severity of illness.